Due to a production error, there was an error in affiliation 1 for author Andria Tziakouri. Instead of “Department of Neurology, Medical School, University of Nicosia, Nicosia, Cyprus,” it should be “Department of Neurology, American Medical Center, Nicosia, Cyprus.”
The publisher apologizes for this mistake. The original version of this article has been updated.
Summary
Keywords
erenumab, chronic migraine, quality of life, MSQ V2.1, Cyprus, treatment failure
Citation
Frontiers Production Office (2021) Erratum: Assessment of the Effect of Erenumab on Efficacy and Quality-of-Life Parameters in a Cohort of Migraine Patients With Treatment Failure in Cyprus. Front. Neurol. 12:793620. doi: 10.3389/fneur.2021.793620
Received
12 October 2021
Accepted
12 October 2021
Published
03 November 2021
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
12 - 2021
Updates
Copyright
© 2021 Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office production.office@frontiersin.org
This article was submitted to Headache and Neurogenic Pain, a section of the journal Frontiers in Neurology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.